Since those landmark 1992 [38] and 1993 [34] studies, the MIB1 monoclonal antibody against the Ki-67 antigen has been universally used for almost 30 years to determine the proliferation characteristics of hematopoietic malignancies and solid tumors, including breast cancer. Here, MKI67 is linked to breast carcinoma.